U.S. Contrast Agent and Radiopharmaceutical Market Snapshot
The US contrast agent and radiopharmaceutical market will witness moderate growth over the forecast period. Growth will be driven by increasing PET and MRI procedure volumes, as well as broader adoption of imaging agents in CEUS and PET applications. However, market expansion will be constrained by ongoing concerns regarding gadolinium retention and radiation exposure associated with certain imaging modalities. In addition, the transition to value-based care will limit utilization of some procedures, favoring those that deliver superior diagnostic accuracy and visualization quality. Looking ahead, growth will be supported by the introduction of new contrast agents currently in development or clinical evaluation, as well as FDA approvals that expand the indications of existing agents.
Read our Market Snapshot to access comprehensive data and analysis on the state of the market for contrast agents and radiopharmaceuticals in the US from 2019 through 2035.
